Multinational phase 1 trial of telisotuzumab adizutecan, a novel c-Met-targeting antibody-drug conjugate, for advanced G/GEJ cancer

Gastric/gastroesophageal junction adenocarcinoma (GEA) has a high mortality rate and presents significant treatment challenges.Telisotuzumab adizutecan (Temab-A; ABBV-400) is a novel antibody-drug conjugate targeting c-Met protein. A multinational phase 1 trial evaluated Temab-A monotherapy (3.0 mg/kg every 3 weeks intravenously) in adult patients with advanced GEA who had received one or two prior systemic therapies. Forty-two patients were enrolled; median age was 60 years. Median follow-up duration was 12.6 months. All patients had one or more treatment-emergent adverse events, with 88% grade ≥ 3 TEAEs. The objective response rate was 29%, the clinical benefit rate was 71%, and median duration of response was 4.2 months. Median progression-free survival was 4.0 months, and median overall survival was 5.8 months. The authors conclude that Temab-A monotherapy demonstrated antitumor activity and manageable safety in patients with advanced GEA. These findings support further clinical development of Temab-A.